---
title: 'Male hypogonadism: pathogenesis, diagnosis, and management'
date: '2024-08-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39159641/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240820182437&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Organic male hypogonadism due to irreversible hypothalamic-pituitary-testicular
  (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy.
  However, controversy surrounds the global practice of prescribing testosterone to
  symptomatic men with low testosterone and non-gonadal factors reducing health status,
  such as obesity, type 2 diabetes, and ageing (ie, functional hypogonadism), but
  without identifiable HPT axis pathology. Health optimisation remains ...
disable_comments: true
---
Organic male hypogonadism due to irreversible hypothalamic-pituitary-testicular (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy. However, controversy surrounds the global practice of prescribing testosterone to symptomatic men with low testosterone and non-gonadal factors reducing health status, such as obesity, type 2 diabetes, and ageing (ie, functional hypogonadism), but without identifiable HPT axis pathology. Health optimisation remains ...